CDCP1 Antibody (U.California patent anti-CDCP1) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28720F
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # U.California patent anti-CDCP1
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for CDCP1 Antibody (U.California patent anti-CDCP1) [FITC]
Immunogen
CDCP1 / CD318
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for CDCP1 Antibody (U.California patent anti-CDCP1) [FITC]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CDCP1
Long Name
CUB Domain Containing Protein 1
Alternate Names
CD318, SIMA135
Gene Symbol
CDCP1
Additional CDCP1 Products
Product Documents for CDCP1 Antibody (U.California patent anti-CDCP1) [FITC]
Product Specific Notices for CDCP1 Antibody (U.California patent anti-CDCP1) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...